Remimazolam-Based Anesthesia in Patients with Heart Failure Due to Mitral Regurgitation and Low Left Ventricular Function: A Case Series

Overview

Journal Medicina (Kaunas)

Publisher MDPI

Specialty General Medicine

Date 2023 Dec 23

PMID 38138239

Authors

Atsuhiro Kitaura

Hiroatsu Sakamoto

Shinichi Hamasaki

Shota Tsukimoto

Yasufumi Nakajima

Affiliations

Soon will be listed here.

Abstract

: Remimazolam is a new ultrashort-acting benzodiazepine anesthetic. Remimazolam appears to be useful in patients with severe valvular disease because of its minimal cardiovascular impact. In this retrospective case series study, we assessed the efficacy and safety of remimazolam for maintaining hemodynamic stability during anesthetic induction and maintenance. : MitraClip was performed on 18 cases with severe mitral regurgitation with low left ventricular function who presented with heart failure, and remimazolam was administered for general anesthesia with induction (12 mg/kg/h) and maintenance (1 mg/kg/h). The impact of remimazolam on the hemodynamics at anesthetic induction and during anesthetic maintenance was investigated retrospectively using electronic medical records. Blood pressure decreased significantly during anesthetic induction with remimazolam (78.5 [72, 81.25] and 66.1 [62.2, 74.2], median [IQR], = 0.0001), but only mildly, by about 10 mmHg. There was no significant change in the cardiac index (2.0 [1.8, 2.4] vs. 1.9 [1.8, 2.3], = 0.57642) or pulse rate (73.5 ± 8.85 vs. 74.7 ± 11.7, mean ± SD, = 0.0876) during anesthetic induction with remimazolam. All patients underwent MitraClip without major hemodynamic concerns, with no or small increases in inotropes. Remimazolam may be used safely in patients with severe mitral regurgitation and low left ventricular function presenting with heart failure.

References

Ito H, Kameyama A, Furuta M, Yoshida M, Onishi K, Kawakami M . Anesthetic Management Using Remimazolam for Transcatheter Edge-to-Edge Repair of the Mitral Valve in Patients With Reduced Ejection Fraction: A Case Report of Two Cases. Cureus. 2022; 14(10):e30706. PMC: 9697736. DOI: 10.7759/cureus.30706. View

Furuta M, Ito H, Yamazaki M . Anaesthetic management using remimazolam in a patient with severe aortic stenosis: a case report. BMC Anesthesiol. 2021; 21(1):202. PMC: 8364063. DOI: 10.1186/s12871-021-01422-6. View

Kitaura A, Tsukimoto S, Sakamoto H, Hamasaki S, Nakao S, Nakajima Y . A retrospective comparative study of anesthesia with remimazolam and remifentanil versus dexmedetomidine and remifentanil for transcatheter aortic valve replacement. Sci Rep. 2023; 13(1):17074. PMC: 10564871. DOI: 10.1038/s41598-023-43895-0. View

Borkett K, Riff D, Schwartz H, Winkle P, Pambianco D, Lees J . A Phase IIa, randomized, double-blind study of remimazolam (CNS 7056) versus midazolam for sedation in upper gastrointestinal endoscopy. Anesth Analg. 2014; 120(4):771-80. DOI: 10.1213/ANE.0000000000000548. View

Deng H, Li F, Cai Y, Xu S . Waste anesthetic gas exposure and strategies for solution. J Anesth. 2018; 32(2):269-282. DOI: 10.1007/s00540-018-2448-1. View

Satoh T, Nishihara N, Sawashita Y, Ohno S, Hirata N, Yamakage M . Remimazolam Anesthesia for MitraClip Implantation in a Patient with Advanced Heart Failure. Case Rep Anesthesiol. 2021; 2021:5536442. PMC: 8116154. DOI: 10.1155/2021/5536442. View

Doi M, Morita K, Takeda J, Sakamoto A, Yamakage M, Suzuki T . Efficacy and safety of remimazolam versus propofol for general anesthesia: a multicenter, single-blind, randomized, parallel-group, phase IIb/III trial. J Anesth. 2020; 34(4):543-553. DOI: 10.1007/s00540-020-02788-6. View

Hari Y, Satomi S, Murakami C, Narasaki S, Morio A, Kato T . Remimazolam decreased the incidence of early postoperative nausea and vomiting compared to desflurane after laparoscopic gynecological surgery. J Anesth. 2022; 36(2):265-269. DOI: 10.1007/s00540-022-03041-y. View

Cohen I, Finkel J, Hannallah R, Hummer K, Patel K . Rapid emergence does not explain agitation following sevoflurane anaesthesia in infants and children: a comparison with propofol. Paediatr Anaesth. 2003; 13(1):63-7. DOI: 10.1046/j.1460-9592.2003.00948.x. View

10.

Kilpatrick G, McIntyre M, Cox R, Stafford J, Pacofsky G, Lovell G . CNS 7056: a novel ultra-short-acting Benzodiazepine. Anesthesiology. 2007; 107(1):60-6. DOI: 10.1097/01.anes.0000267503.85085.c0. View

11.

Wiltshire H, Kilpatrick G, Tilbrook G, Borkett K . A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part II. Population pharmacokinetic and pharmacodynamic modeling and simulation. Anesth Analg. 2012; 115(2):284-96. DOI: 10.1213/ANE.0b013e318241f68a. View

12.

Kitaura A, Kosumi R, Iwamoto T, Nakao S . Remimazolam anesthesia for transcatheter mitral valve repair in a patient with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome: a case report. JA Clin Rep. 2022; 8(1):38. PMC: 9160163. DOI: 10.1186/s40981-022-00528-1. View

13.

Franken L, de Winter B, Masman A, Dijk M, Baar F, Tibboel D . Population pharmacodynamic modelling of midazolam induced sedation in terminally ill adult patients. Br J Clin Pharmacol. 2017; 84(2):320-330. PMC: 5777431. DOI: 10.1111/bcp.13442. View

14.

Masui K . Remimazolam besilate, a benzodiazepine, has been approved for general anesthesia!!. J Anesth. 2020; 34(4):479-482. DOI: 10.1007/s00540-020-02755-1. View

15.

Doi M, Hirata N, Suzuki T, Morisaki H, Morimatsu H, Sakamoto A . Safety and efficacy of remimazolam in induction and maintenance of general anesthesia in high-risk surgical patients (ASA Class III): results of a multicenter, randomized, double-blind, parallel-group comparative trial. J Anesth. 2020; 34(4):491-501. DOI: 10.1007/s00540-020-02776-w. View